Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke
https://doi.org/10.21518/ms2024-404
Abstract
Introduction. Stroke remains one of the major causes of death in type diabetes mellitus (DM). Injectable form of glucagon-like peptide-1 receptor agonist semaglutide, Ozempic® decreases the stroke risk. In Russia there appeared a biosimilar Semavic® but its effects on the brain are not yet studied.
Aim. To compare neuroprotective properties of Semavic® and Ozempic® while used before ischemic stroke in rats without DM.
Materials and methods. The study was conducted in male Wistar rats that were divided into the following groups: “Control” (n = 10) – 0.9% NaCl, “MET” (n = 9) – metformin 200 mg/kg once daily per os, “Ozempic” (n = 10) – Ozempic® 0.012 mg/kg s.c. once daily, “Semavic” (n = 9) – Semavic® 0.012 mg/kg s.c. once daily. After 7 days ischemic stroke was modelled, after 48 hour of reperfusion neurological deficit and brain damage volume were evaluated. Glycemia was measured on the 3rd, 7th days as well as during and after ischemia.
Results. None of the study drugs caused hypoglycemia including in poststroke period. Neurological deficit in “MET” group did not differ from that in the “Control” (11.00 [6.50; 12.50] and 10.0 [6.25; 12.00] scores). Both semaglutide drugs caused comparable improvement in neurological status (14.00 [12.00; 18.00] and 14.00 [11.00; 18.00] scores in “Ozempic” and “Semavic” groups). Brain necrosis volume in “Control” group was 16.60 [13.40; 28.58] %. All the study drugs had infarct-limiting effect but brain damage volume in “Ozempic” (6.00 [4.32; 8.44] %) and “Semavic” (7.69 [2.99; 11.33] %) was smaller than in “MET” group (13.07 [8.67; 29.94] %). There were no differences between semaglutide drugs.
Conclusions. Biosimilar Semavic® and original Ozempic® demonstrate comparable neuroprotective effect while used in animals without DM prior to ischemic stroke modelling. This protective effect is not due to the drugs’ influence on glycemic profile.
About the Authors
T. L. Karonova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Tatiana L. Karonova, Dr. Sci. (Med.), Head of the Scientific Research Laboratory of New Coronavirus Infection and Postcovid Syndrome of the World-Class Scientific Center “Center for Personalized Medicine”, Chief Researcher of the Research Laboratory of Clinical Endocrinology of the Institute of Endocrinology, Professor of the Department of Endocrinology
2, Akkuratov St., St Petersburg, 197341
A. V. Murasheva
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Anna V. Murasheva, Cand. Sci. (Med.), Senior Researcher at the Research Laboratory of Clinical Endocrinology of the Institute of Endocrinology, Associate Professor of the Department of Faculty Therapy with the Clinic
2, Akkuratov St., St Petersburg, 197341
N. V. Timkina
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Natalya V. Timkina, Junior Researcher at the Research Laboratory of Clinical Endocrinology of the Institute of Endocrinology
2, Akkuratov St., St Petersburg, 197341
O. S. Fuks
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Oksana S. Fuks, Laboratory Assistant Researcher at the Scientific Research Laboratory of New Coronavirus Infection and Postcovid Syndrome of the World-Class Scientific Center “Center for Personalized Medicine”
2, Akkuratov St., St Petersburg, 197341
E. V. Shlyakhto
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Evgeny V. Shlyakhto, Acad. RAS, Dr. Sci. (Med.), Professor, General Manager
2, Akkuratov St., St Petersburg, 197341
References
1. Dedov II, Shestakova MV, Vikulova OK, Zheleznyakova AV, Isakov MA, Sazonova DV, Mokrysheva NG. Diabetes mellitus in the Russian Federation: dynamics of epidemiological indicators according to the Federal Register of Diabetes Mellitus for the period 2010–2022. Diabetes Mellitus. 2023;26(2):104–123. (In Russ.) https://doi.org/10.14341/DM13035.
2. Mosenzon O, Cheng AY, Rabinstein AA, Sacco S. Diabetes and Stroke: What Are the Connections? J Stroke. 2023;25(1):26–38. https://doi.org/10.5853/jos.2022.02306.
3. Tang H, Zhang S, Yan S, Liebeskind DS, Sun J, Ding X et al. Unfavorable neurological outcome in diabetic patients with acute ischemic stroke is associated with incomplete recanalization after intravenous thrombolysis. J Neurointerv Surg. 2016;8(4):342–346. https://doi.org/10.1136/neurintsurg-2014-011643.
4. Saxena A, Anderson CS, Wang X, Sato S, Arima H, Chan E et al. Prognostic Significance of Hyperglycemia in Acute Intracerebral Hemorrhage: The INTERACT2 Study. Stroke. 2016;47(3):682–688. https://doi.org/10.1161/STROKEAHA.115.011627.
5. Lau LH, Lew J, Borschmann K, Thijs V, Ekinci EI. Prevalence of diabetes and its effects on stroke outcomes: A meta-analysis and literature review. J Diabetes Investig. 2019;10(3):780–792. https://doi.org/10.1111/jdi.12932.
6. Dedov II, Shestakova MV, Mayorov AYu, Mokrysheva NG, Andreeva EN, Bezlepkina OB et al. Standards of Specialized Diabetes Care / Edited by Dedov II, Shestakova MV, Mayorov AYu. 11th Edition. Diabetes Mellitus. 2023;26(2S):1–157. (In Russ.) https://doi.org/10.14341/DM13042.
7. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(12):2753–2786. https://doi.org/10.2337/dci22-0034.
8. Bellastella G, Maiorino MI, Longo M, Scappaticcio L, Chiodini P, Esposito K, Giugliano D. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With MetaAnalysis. Stroke. 2020;51(2):666–669. https://doi.org/10.1161/STROKEAHA.119.027557.
9. Arefeva AN, Banko VV, Sadovskikh MO, Noskov SM. Pharmacokinetics of first semaglutid drug in Russian Federation: results of open-label randomized clinical trial. Meditsinskiy Sovet. 2023;17(16):77–82. (In Russ.) https://doi.org/10.21518/ms2023-312.
10. Yang X, Feng P, Zhang X, Li D, Wang R, Ji C et al. The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of stroke. Neuropharmacology. 2019;158:107748. https://doi.org/10.1016/j.neuropharm.2019.107748.
11. Karimipour M, Shojaei Zarghani S, Mohajer Milani M, Soraya H. Pre-Treatment with Metformin in Comparison with Post-Treatment Reduces Cerebral Ischemia Reperfusion Induced Injuries in Rats. Bull Emerg Trauma. 2018;6(2):115–121. https://doi.org/10.29252/beat-060205.
12. Koizumi J. Experimental Studies of Ischemic Brain Edema. A New Experimental Model of Cerebral Embolism in Rats in Which Recirculation Can Be Introduced in the Ischemic Area. Japan J Stroke. 1986;8:1–8. https://doi.org/10.3995/jstroke.8.1.
13. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20(1):84–91. https://doi.org/10.1161/01.str.20.1.84.
14. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke. 1995;26(4):627–634. https://doi.org/10.1161/01.str.26.4.627.
15. De Oliveira JC, Ludemann Camargo R, Barella LF, Chaves Souto Branco R, Gravena C, Grassiolli S et al. Anesthetic-induced transient hyperglycemia and insulin resistance do not depend on the sympathoadrenal axis. Minerva Endocrinol. 2013;38(4):379–388. Available at: https://pubmed.ncbi.nlm.nih.gov/24285105.
16. Saha JK, Xia J, Grondin JM, Engle SK, Jakubowski JA. Acute hyperglycemia induced by ketamine/xylazine anesthesia in rats: mechanisms and implications for preclinical models. Exp Biol Med. 2005;230(10):777–784. https://doi.org/10.1177/153537020523001012.
17. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–1844. https://doi.org/10.1056/NEJMoa1607141.
18. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–851. https://doi.org/10.1056/NEJMoa1901118.
19. Basalay MV, Davidson SM, Yellon DM. Neuroprotection in Rats Following Ischaemia-Reperfusion Injury by GLP-1 Analogues-Liraglutide and Semaglutide. Cardiovasc Drugs Ther. 2019;33(6):661–667. https://doi.org/10.1007/s10557-019-06915-8.
20. Simanenkova AV, Fuks OS, Timkina NV, Tikhomirova PA, Vlasov TD, Karonova TL. Neuroprotective effects of glucose-lowering drugs in rat focal brain ischemia-reperfusion model. Arterial Hypertension (Russian Federation). 2023;29(6):579–592. (In Russ.) https://doi.org/10.18705/1607-419X-2023-29-6-579-592.
Review
For citations:
Karonova TL, Murasheva AV, Timkina NV, Fuks OS, Shlyakhto EV. Comparative study of the neuroprotective potential of semaglutide injectable preparations in experimental ischemic stroke. Meditsinskiy sovet = Medical Council. 2024;(16):163-170. (In Russ.) https://doi.org/10.21518/ms2024-404
Views:
188
Email this article 